Drug Profile
Research programme: siRNA therapeutics - Quark Pharmaceuticals/Pfizer
Alternative Names: CTi-1; CTPi-1; QP-CO1; QP-LI2; RNA interference based therapeuticsLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Quark Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference; Small interfering RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute lung injury; Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Parenteral)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Acute-lung-injury in USA
- 30 Jan 2020 Preclinical development for Acute lung injury and Chronic obstructive pulmonary disease is ongoing USA